Caldwell Sutter Capital, Inc. Vaxcyte, Inc. Transaction History
Caldwell Sutter Capital, Inc.
- $215 Billion
- Q4 2024
A detailed history of Caldwell Sutter Capital, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Caldwell Sutter Capital, Inc. holds 432 shares of PCVX stock, worth $38,871. This represents 0.02% of its overall portfolio holdings.
Number of Shares
432
Previous 379
13.98%
Holding current value
$38,871
Previous $43.3 Million
18.34%
% of portfolio
0.02%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding PCVX
# of Institutions
358Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$1.03 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$983 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$894 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$782 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$441 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.34B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...